Corelia Bio - About the company
Corelia Bio is an unfunded company based in Gottingen (Germany), founded in 2026. It operates as a Developer of engineered human tissue models for cardio-renal research. Corelia Bio has not raised any funding yet. The company has 541 active competitors, including 171 funded and 85 that have exited. Its top competitors include companies like MedGenome, Aspen Neuroscience and Biocytogen.
Company Details
Developer of engineered human tissue models for cardio-renal research. This organization creates systems that simulate chronic kidney disease and associated cardiac injury to investigate biological mechanisms and drug responses. It provides a research platform that utilizes artificial intelligence to organize evidence and assist in framing study questions for translational development programs. The technology enables the evaluation of contractility, structural remodeling, and molecular signaling within engineered myocardial modules.
Key Metrics
Sign up to download Corelia Bio's company profile
Corelia Bio's funding and investors
Corelia Bio has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Corelia Bio's Competitors and alternates
Top competitors of Corelia Bio include MedGenome, Aspen Neuroscience and Biocytogen. Here is the list of Top 10 competitors of Corelia Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Provider of DNA sequencing, bioinformatics, and multiomics services | $264M | 70/100 | ||
2nd | Aspen Neuroscience 2018, San Diego (United States), Public | Provider of genomic-based personalised pluripotent stem cell therapy | $339M | 69/100 | |
3rd | Biocytogen 2008, Wakefield (United States), Public | Provider of integrated solutions for next-generation antibody drug development | $301M | 69/100 | |
4th | Personalis 2011, Menlo Park (United States), Acquired | Provider of genomic sequencing and diagnosis software for the healthcare industry | $87.3M | 68/100 | |
5th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 67/100 | |
6th | Applied StemCell 2008, Milpitas (United States), Acquired | Provider of animal and cell line models as tools for drug discovery and diagnostics | $67.5M | 66/100 | |
7th | Developer of regenerative medicine and 3D tissues | $52.1M | 65/100 | ||
8th | InSphero 2009, Schlieren (Switzerland), Series D | Developer of cell based assays for drug screening | $35M | 64/100 | |
9th | Blue Rock Therapeutics 2016, Boston (United States), Acquired | Stem cell therapies for cardiovascular and neurological diseases | $225M | 64/100 | |
10th | UniQure 1998, Amsterdam (Netherlands), Public | Developer of gene-based therapies for patients with genetic or acquired diseases | $111M | 63/100 | |
690th | Corelia Bio 2026, Gottingen (Germany), Unfunded | Developer of engineered human tissue models for cardio-renal research | - | - | - |
Looking for more details on Corelia Bio's competitors? Click here to see the top ones
Corelia Bio's Investments and acquisitions
Corelia Bio has made no investments or acquisitions yet.
Reports related to Corelia Bio
Here is the latest report on Corelia Bio's sector:
Are you a Founder ?
FAQs about Corelia Bio
Explore our recently published companies
- Copilot Manufacturing - Lufkin based, 2026 founded, Unfunded company
- Cookezee - Bengaluru based, 2026 founded, Unfunded company
- Cookies and Tokens - Toronto based, 2026 founded, Unfunded company
- Cool Runnings - Germany based, 2026 founded, Unfunded company
- ConvoClin - New York based, 2026 founded, Unfunded company
- Conversation Coach - United Kingdom based, 2026 founded, Unfunded company